Multicenter Phase II Trial of High-Dose Interleukin (IL-2) With Priming and Concomitant Sargramostim (GM-CSF) in Patients With Advanced Melanoma.
Phase of Trial: Phase II
Latest Information Update: 02 May 2012
At a glance
- Drugs Interleukin-2; Sargramostim
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 02 May 2012 Actual patient number is 36 according to ClinicalTrials.gov.
- 23 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.